Strategy & Consultancy for Health & Wellbeing — The Practitioner’s Playbook.

SectionThe honest reframe most consultancies won't tell you

Generic strategy consultancies sell dental groups, private GP practices, optician chains, physiotherapy networks and aesthetic clinics the same deck they sold a fast-casual restaurant chain last quarter — Porter's Five Forces, a SWOT, a McKinsey horizons grid, a vague "operational excellence" workstream, a £45,000 invoice. Then the founder sits with the bound document, looks at their P&L, and realises nothing in those slides tells them whether to open clinic three or staff up clinic two.

Health and wellbeing operators don't need generic strategy. They need strategy work that reckons with the actual economics of this category — multi-clinic expansion maths where rent, clinician utilisation and chair / room ratio decide whether site three is viable; NHS-versus-private mix-shift decisions that change cash conversion by 60+ days; treatment-mix margin engineering where a £180 hygienist appointment subsidises a £3,400 implant case; clinician-acquisition and retention strategy in a labour market where a single associate leaving costs £80,000 in re-recruitment plus lost case work; and a CQC-aligned operating model that survives an inspection without burning the founder's weekend for three months.

Generic consultancies don't ship this stack because they don't know which levers move EBITDA in a regulated, clinician-led, capacity-constrained business. This playbook fixes the structure. The expansion economics is the multiplier. The treatment-mix margin engineering is the compounding lever. The CQC-aligned operating model is the floor you can't go below. Read it, run it yourself, or have us ship it on retainer.

SectionThe eight-point audit we run on day one

1. Multi-clinic expansion economics — Rent, chair / room ratio, clinician utilisation rate, payback months, net contribution by site at month 12 / 18 / 24. Most multi-clinic founders are running on instinct and a spreadsheet that hasn't been touched since site two opened. We rebuild the model from first principles, with sensitivity ranges on the three variables that actually move the answer.
2. NHS-versus-private mix-shift strategy — For dental and physio in particular: what proportion of chair-time is NHS UDA delivery, what's private fee-per-item, what's plan-based recurring revenue, and what's the optimal mix given current clinician roster, demographic catchment, and cash-flow tolerance. Mix-shift decisions made on instinct cost six-figure sums in deferred margin or surrendered NHS contract penalties.
3. Treatment-mix margin engineering — Procedure-level contribution margin analysis. Hygienist appointments, check-ups, scale-and-polish, fillings, root canals, implants, ortho, aesthetics. Which treatments subsidise which? Where is the practice running a loss-leader without realising it? Which treatments should be ring-fenced for senior clinicians versus delegated?
4. Clinician-acquisition and retention strategy — The locum-versus-employed-versus-partner question, treated as a strategic decision rather than a recruitment afterthought. Locum maths, associate package design, partnership pathway design, equity / phantom equity options, non-competes that actually hold up, GMC / GDC / GOC indemnity treatment.
5. CQC-aligned operating model and audit-readiness — Registered Manager structure, governance cadence, clinical audit programme, safeguarding lead, infection-prevention lead, mock-inspection readiness. The difference between a "Good" and a "Requires improvement" rating is operating-model design, not luck.
6. Pricing-pack architecture: entry / standard / premium — Three-tier pricing pack design across treatments, with anchored entry tier, profitable standard tier, and aspirational premium tier. Most clinics have a single price list and leave 15–25 percent of revenue on the table.
7. Brand-level versus clinic-level strategic decision-rights — In multi-site groups: what is decided at brand HQ (pricing pack, clinical protocols, supplier contracts, marketing voice), what is decided at clinic level (rota, locum cover, local referrals, community partnerships), and where the decision-rights ambiguity is currently destroying speed and margin.
8. Board-level OKRs aligned to clinical and commercial targets — Quarterly objectives + key results that bind clinical quality (audit scores, complaint rates, recall compliance) to commercial performance (revenue per chair-hour, gross margin, EBITDA, cash conversion). One scoreboard the founder, the Registered Manager and the senior clinicians all read off.

Three or more reds — fix the foundation before commissioning new sites, new hires or new marketing spend.

SectionSix productised deliverables we ship per cycle

Multi-clinic expansion economics model. A live model — not a static deck — that runs scenarios on rent, chair / room ratio, clinician utilisation, NHS / private mix and ramp curve. Output: site-three go / no-go with payback months, year-three EBITDA contribution, and the three variables that change the answer if they move ten percent. Built to be re-run by the founder each quarter without our involvement, with a Monte Carlo overlay on the ramp assumption so the downside case isn't a guess. Time to first signal: 21 days.

NHS-versus-private mix-shift strategy. Procedure-level analysis of current chair-time allocation, contribution per treatment family, cash-conversion delta NHS-versus-private, and a phased mix-shift plan with quarterly milestones. Includes a UDA-contract reduction-and-surrender risk register, plan-based revenue ramp model, and patient-segmentation analysis against catchment Mosaic / ACORN data. Founder gets a clear answer to "do we keep the NHS contract, reduce it, or surrender it" with the maths visible, the contract-penalty exposure quantified, and the patient-attrition risk modelled. Time to first signal: 30 days.

Treatment-mix margin engineering. Contribution-margin matrix across all treatments delivered, with current versus target mix, identified loss-leaders, identified under-priced premium treatments, and a clinician-by-clinician treatment-allocation map. Output: a six-month operational change-plan that lifts gross margin two-to-five points without raising prices, plus a recall-pathway redesign that captures lapsed-patient revenue at six- and 12-month windows.

Clinician-acquisition and retention strategy. Locum-versus-employed-versus-partner decision framework with the actual labour-market maths for the practice's geography and specialty. Associate package design with worked examples. Partnership pathway with equity / phantom equity options. Non-compete and restrictive covenant review against current GDC / GMC / GOC / HCPC case law. Clinician-NPS instrumentation, exit-interview process, and a 90-day onboarding pack that gets new associates to break-even faster. Output: a 12-month clinician roster plan with named risk register and a backfill scenario for each senior clinician.

CQC-aligned operating model audit. Full governance review against the five Key Lines of Enquiry — Safe, Effective, Caring, Responsive, Well-led. Registered Manager role design, clinical audit programme design, safeguarding and IPC lead structures, mock-inspection workbook. Output: a written red / amber / green of inspection-readiness with named owners and dated remediation steps, plus a quarterly governance calendar that runs itself once installed. Designed to survive a Registered Manager handover without the founder rebuilding the operating model from memory.

Pricing-pack architecture. Three-tier pricing design across treatments — entry, standard, premium — with anchored psychology, ASA / GDC / GMC / MHRA-compliant claim wording, finance-option structuring (zero-percent, regulated BNPL, plan-based recurring), and a six-month rollout plan. Output: a single approved price list, a clinician-facing script for handling the price-rise conversation with existing patients, and the change-management plan to land it without losing more than three percent of the active patient base.

SectionWhat to do this week

1. Pull the last 12 months of treatment-level revenue. Owner: founder or finance lead. Time: 60 minutes. Export the full procedure-level revenue and volume from the practice management system (SOE, Dentally, Carestream, Optix, similar). Most founders haven't looked at this view in 18 months. The picture is usually surprising.
2. Calculate revenue per chair-hour or room-hour. Owner: founder. Time: 45 minutes. Total revenue divided by available chair-hours or room-hours per site, per month. Benchmark against the £180–£420 per chair-hour range typical for UK private dental, the £140–£280 range for private GP, the £90–£160 range for physio. Where you sit on that range is the headline diagnostic.
3. Decide DIY, DWY or DFY for the next 90 days. Owner: founder. See the three ways.

SectionFive questions healthcare operators ask us about strategy

We've got two clinics running well — should we open a third now or consolidate? The answer depends on three variables: chair / room utilisation at sites one and two (if either is below 70 percent, fix utilisation before adding capacity), the strength of the senior clinician bench (a third site needs a clinical lead who isn't the founder), and the cash position (site three typically takes 14–22 months to payback, and consumes £180,000–£420,000 in fit-out and ramp). The expansion economics model gives you a number. We will not tell you to open or hold without it.

How much NHS work should we keep? It's not a binary. The optimal mix depends on chair-time supply, demographic catchment private-pay willingness, the cash-conversion delta (NHS UDAs settle on a different cycle than private fee-per-item or plan-based revenue), and contract-surrender penalties. We model it. Most multi-site dental groups we've worked with end up in a 30–60 percent private mix that's higher than where they started, without a wholesale NHS exit.

Our best associate is threatening to leave — how do we keep them? Retention is rarely a pay problem alone. It's package design (basic versus performance versus equity), case-mix allocation (are they getting the implants and the orthodontics, or just the routine), career pathway (is partnership real or theoretical), and clinical autonomy (do they own their list). A retention conversation that opens with "what would it take" without those four levers diagnosed first usually ends with a counter-offer that's still not enough.

What does a CQC-aligned operating model actually look like in practice? A named Registered Manager with the time and authority to do the role; a clinical governance meeting that runs to a published agenda monthly; a clinical audit programme that completes a minimum of four audits per year against KLOE-mapped standards; a safeguarding lead and an IPC lead with documented training; a complaints log that's reviewed at every governance meeting; and a mock-inspection workbook that any senior clinician can answer from. It's process, not paperwork. The "Outstanding" rated practices we've worked with have the exact same documentation as "Requires improvement" — they just live by it instead of filing it.

What about aesthetics — the regulatory environment is changing, where does that leave the strategy? The 2025–2026 tightening of MHRA, JCCP and the Botulinum-toxin / dermal-filler licensing scheme has changed the strategic question from "how fast can we grow the aesthetics arm" to "how do we structure the aesthetics arm to be the practice that's still standing when the regulator clears the unlicensed operators". For most operators that means prescriber-led models, named clinician accountability on every treatment, ASA / CAP-compliant marketing that we'd ship for any other regulated treatment, and a price-pack that doesn't compete on the bottom of the market. The strategic upside has actually widened — the field of legitimate competitors is shrinking.

Can we run this ourselves with the playbook plus the £750 audit? The expansion economics model and the treatment-mix margin engineering are achievable in-house if the founder has a finance lead with strong Excel and 60–80 hours of focused capacity. The CQC operating model rebuild benefits from external eyes — internal teams underweight gaps they've lived with for years. The clinician-acquisition and retention strategy is the deliverable most founders try to do themselves and most regret afterwards, because the package design and partnership-pathway maths is genuinely hard and the cost of getting it wrong is a senior associate walking. The £750 audit gives you a written red / amber / green of all eight points plus named-owner / dated next steps, and a 60-minute working session to walk through the findings with the founder and the senior leadership. Credit toward first cycle if you sign for DWY or DFY within 30 days.

SectionWhere to go from here

If you want this shipped end-to-end on a productised retainer, book a 30-minute discovery call.

If you'd rather have weekly senior coaching, the coaching plans start at £750/month — the right call when the founder is doing the strategic thinking themselves and wants a senior sparring partner once a week. The two-week embedded sprint at £3,000 fixed is the right call for new-clinic launch decisions, NHS-versus-private mix-shift sequencing, or pre-CQC inspection strategy work where the deadline is non-negotiable.

Or run it yourself. Eight-point audit, one deliverable a month, twice-quarterly office hours.